Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations

@article{Gambarin2009RationaleAD,
  title={Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations},
  author={F. Gambarin and V. Favalli and A. Serio and M. Regazzi and M. Pasotti and C. Klersy and R. Dore and S. Mannarino and M. Vigan{\'o} and A. Odero and S. Amato and L. Tavazzi and E. Arbustini},
  journal={Journal of Cardiovascular Medicine},
  year={2009},
  volume={10},
  pages={354–362}
}
Background The major clinical problem of Marfan syndrome (MFS) is the aortic root aneurysm, with risk of dissection when the root diameter approximates 5 cm. In MFS, a key molecule, transforming growth factor-β (TGF-β), normally bound to the extracellular matrix, is free and activated. In an experimental setting, TGF-β blockade prevents the aortic root structural damage and dilatation. The angiotensin receptor 1 blockers (sartanics) exert an anti-TGF-β effect; trials are now ongoing for… Expand

Paper Mentions

Interventional Clinical Trial
The major clinical problems in patients with Marfan Syndrome (MFS) are aortic root dilation (ARD), dissection and rupture. Although the available treatments (beta-blockers, BBs) improve… Expand
ConditionsMarfan Syndrome
InterventionDrug
An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome.
Medical Treatment of Aortic Aneurysms in Marfan Syndrome and other Heritable Conditions
Atenolol versus losartan in children and young adults with Marfan's syndrome.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
...
1
2
3
4
5
...